Form 4: enGene Holdings Director Gerald Brunk Granted 22,500 Stock Options

enGene Holdings Inc. Director and 10% Owner Gerald A. Brunk was granted 22,500 stock options with an exercise price of $3.31, vesting over the next year or by the 2026 Annual Meeting of Shareholders.

Summary

• Gerald A. Brunk, a Director and 10% Owner of enGene Holdings Inc. (ENGN), was granted 22,500 stock options.
• The options have an exercise price of $3.31 per share.
• The grant date for these options was June 16, 2025, and they expire on June 16, 2035.
• The options will fully vest on the earlier of June 10, 2026 (first anniversary of vesting commencement) or the 2026 Annual Meeting of Shareholders.
• Mr. Brunk holds these options for the benefit of several Lumira Entities (Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck Lumira Biosciences Fund, L.P., and Merck Lumira Biosciences Fund (Quebec), L.P.) and expressly disclaims beneficial ownership.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options to a director and 10% owner is a standard compensation practice that aligns interests, but the filing itself is purely a disclosure and doesn't contain performance data.

Positives

• The grant of stock options to a director and 10% owner aligns management and significant shareholder interests with long-term company performance.
• The exercise price of $3.31 provides an incentive for the director to contribute to share price appreciation.

Future Outlook

The vesting schedule for the granted stock options indicates a future milestone for the reporting person's equity compensation, tied to either the first anniversary of vesting commencement (June 10, 2026) or the 2026 Annual Meeting of Shareholders.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transaction, common in publicly traded companies, particularly in the biotechnology or pharmaceutical sector where equity compensation is a standard practice to incentivize directors and executives. It does not provide broader industry trends but reflects ongoing corporate governance and compensation practices.

Related Party Transactions

• The stock options are held by Mr. Brunk for the benefit of several Lumira Entities (Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck Lumira Biosciences Fund, L.P., and Merck Lumira Biosciences Fund (Quebec), L.P.).
• Mr. Brunk expressly disclaims beneficial ownership of these securities, indicating a complex beneficial ownership structure related to his role with the Lumira Entities.

Stakeholder Impact

• Shareholders: The grant of options to a director and 10% owner can align their interests with long-term shareholder value creation, as the options gain value if the stock price increases.
• Management/Directors: Gerald A. Brunk receives additional equity compensation, incentivizing his performance and commitment to the company.

Next Steps

• The stock options will fully vest on the earlier of June 10, 2026, or the 2026 Annual Meeting of Shareholders.

Key Dates

Keywords

enGene Holdings Inc., ENGN, Stock Option, Form 4, Insider Transaction, Gerald A. Brunk, Director, 10% Owner, Equity Compensation, SEC Filing, Lumira Ventures